After Hours
$
53.40
Change
-0.01 -0.02%
Volume
Volume 633,882
Jun 24, 2022, 7:58 p.m.
Quotes are delayed by 20 min
Previous close
$ 50.76
$ 53.41
Change
+2.65 +5.22%
Day low
Day high
$49.30
$55.23

52 week low
52 week high
$37.08
$202.73

Market cap
$4.05B
Average volume
1.26M
P/E ratio
N/A
Rev. per Employee
$78,062
EPS
-5.04
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on NTLA
-
Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead
- Barron's Online
-
Intellia Therapeutics started at market perform with $54 stock price target at BMO Capital
- Tomi Kilgore
-
Intellia Stock Has Tumbled. There Are Issues With Gene-Editing Patents.
- Barron's Online
-
Intellia Therapeutics upgraded to outperform from perform at Oppenheimer
- Tomi Kilgore
-
Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases
- Barron's Online
-
Beam Gets FDA Nod for First Gene-Editing Trial
- Barron's Online
-
Prime Is the Newest Gene Editing, and It's Getting Better
- Barron's Online
-
This Fund Is Winning Big by Betting on Stocks That Help Humanity
- Barron's Online
-
Intellia Therapeutics started at buy with $173 stock price target at Stifel Nicolaus
- Tomi Kilgore
-
Intellia Therapeutics stock price target raised to $190 from $90 at Evercore ISI
- Tomi Kilgore
-
The Best and Worst Biopharma Stock Performers So Far in 2021
- Barron's Online
-
Intellia Therapeutics price target raised to $168 from $106 at Raymond James, stock rated outperform
- Tonya Garcia
-
Intellia Therapeutics price target doubled to $160 from $80 at Truist Securities, stock maintained at buy
- Tonya Garcia
-
Intellia Stock Is Rocketing Because of a Gene-Editing Breakthrough
- Barron's Online
-
First In-Vivo Gene Editing Data Look Good for Intellia
- Barron's Online
- Loading more headlines...
Analyst Ratings
-
Benzinga's Top Upgrades, Downgrades For March 8, 2018
- Benzinga.com
-
Breaking Down Barclays' New Bullish Calls On Biotech
- Benzinga.com
-
Benzinga's Top Upgrades, Downgrades For August 29, 2017
- Benzinga.com
Other News on NTLA
-
5 Health Care Stocks Cathie Wood Favors
- GuruFocus.com
-
Graphite Bio: Selling For Much Less Than Net Cash
- Seeking Alpha
-
The Correction In Biopharmaceutical Stocks Is Likely Over
- Seeking Alpha
-
Why Editas Medicine's Shares Fell 28.9% This Week
- Motley Fool
-
Intellia Therapeutics: Several Catalysts Expected For H2 2022
- Seeking Alpha
-
Top 5 1st Quarter Trades of Atlas Venture Associates IX, LLC
- GuruFocus.com
-
ARKG: Don't Expect Any Favorable Return In Short Or Medium Term
- Seeking Alpha
-
10-Q: INTELLIA THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
- Loading more headlines...
Press Releases on NTLA
-
Wednesday's ETF Movers: ARKK, XME
- MarketNewsVideo.com
-
Chau Khuong Joins Catalio Capital Management as General Partner
- BusinessWire - BZX
-
mRNA Vaccine and Therapeutics Market Report 2022, Size, Share, Trends and Forecast to 2027
- SUPER MARKET RESEARCH
-
mRNA Vaccine And Therapeutics Market 2021-2026: Global Size, Share, Trends And Forecast
- SUPER MARKET RESEARCH
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com